提示: 手机请竖屏浏览!

引导CAR T细胞进入实体瘤
Steering CAR T Cells into Solid Tumors


Marion H. Brown ... 肿瘤 • 2019.01.17

本文已被撤稿


 嵌合抗原受体(CAR)T细胞在治疗血液癌症方面取得了惊人的成功1,但迄今对实体瘤无效2。Samaha及其同事最近的一份报告3提出了用于治疗一种实体瘤(胶质母细胞瘤)的CAR T细胞疗法的临床前方案。这些研究者设计了一种CAR T细胞来表达归巢分子(一种黏附分子),归巢分子使得CAR T细胞能够附着到为小鼠胶质母细胞瘤模型供血的血管的内皮细胞上,并迁移通过内皮细胞。他们的方法建立在对肿瘤内皮表型和影响T细胞内皮迁移的黏附途径的详细研究之上。





作者信息

Marion H. Brown, Ph.D., and Michael L. Dustin, Ph.D.
From the Sir William Dunn School of Pathology (M.H.B.) and the Kennedy Institute of Rheumatology (M.L.D.), University of Oxford, Oxford, United Kingdom.

 

参考文献

1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-733.

2. D’Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis 2018;9:282-282.

3. Samaha H, Pignata A, Fousek K, et al. A homing system targets therapeutic T cells to brain cancer. Nature 2018;561:331-337.

4. Major EO. Reemergence of PML in natalizumab-treated patients — new cases, same concerns. N Engl J Med 2009;361:1041-1043.

5. Breuning J, Philip B, Brown MH. Addition of the C-terminus of CD6 to a chimeric antigen receptor enhances cytotoxicity and does not compromise expression. Immunology 2018 October 9 (Epub ahead of print).

服务条款 | 隐私政策 | 联系我们